Study Set Content:
that act through different receptor
mechanisms and produce different toxicities may allow
lowering the dose of the first drug, thus limiting its
toxicity.
Adjunctive Drugs
Use of other (blank) added to
glucocorticoids in treating inflammatory disorders.
immunosuppressive agents
Third, selectively of the drug’s actions may be increased by
(blank) drug available to
receptors in different parts of the body.
manipulating the concentration of
Beneficial and Toxic effects mediated by different types of receptors
Several other drugs were discovered by exploiting therapeutic or toxic effects of chemically(blank) in a clinical context
similar agents
Examples include
quinidine, sulfonylureas, thiazide diuretics,
tricyclic antidepressants, opioid drugs, and phenothiazine
antipsychotics.
Often the new agents turn out to interact with receptors for
(blank) (eg. opioids and phenothiazines for
endogenous opioid and dopamine receptors, respectively.
endogenous substances
so-called because their ligands are
presently unknown, which may prove to be useful targets for
the development of new drugs.
“Orphan” Receptors
1: A lipid-soluble
chemical signal crosses the plasma membrane and acts on an
intracellular
receptor
2: the
signal binds to the (blank) of a transmembrane protein, thereby
activating an (blank) of its cytoplasmic domain;
extracellular domain, enzymatic activity
3: the signal binds to
the extracellular domain of a transmembrane receptor bound to a separate
(blank), which it activates;
protein tyrosine kinase
4: the signal binds to and directly
regulates the opening of an
ion channel
the signal binds to a cell-surface
receptor linked to an effector enzyme by a
G-protein
(blank) cGMP concentration causes
relaxation of vascular smooth muscle by a
kinase-mediated mechanism that results in
(blank) of myosin light chains.
Increased,dephosphorylation
